Roth Capital Initiates Coverage On Rapid Micro Biosystems with Buy Rating, Announces Price Target of $3
Roth Capital analyst Max Masucci initiates coverage on Rapid Micro Biosystems (NASDAQ:RPID) with a Buy rating and announces Price Target of $3.
Stocks · News reference
Rapid Micro Biosystems Q2 EPS $(0.27) Misses $(0.24) Estimate, Sales $8.054M Beat $7.875M Estimate
Rapid Micro Biosystems (NASDAQ:RPID) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.24) by 12.5 percent. This is unchanged from the same period last year. The company
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Rapid Micro Biosystems shares are trading lower after the company reported mixed Q2 financial results.
8-K filing — RAPID MICRO BIOSYSTEMS, INC. (RPID)
Filed: 2026-08-07 AccNo: 0001380106-26-000097 Size: 302 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Rapid Micro Biosystems Affirms FY2026 Sales Guidance of $37.000M-$41.000M vs $39.133M Est
Rapid Micro Biosystems (NASDAQ:RPID) affirms FY2026 sales outlook from $37.000 million-$41.000 million to $37.000 million-$41.000 million vs $39.133 million estimate.